- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03652792
Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers
August 28, 2018 updated by: Lee's Pharmaceutical Limited
Single-Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Azilsartan Tablets in Chinese Healthy Volunteers
The purpose of this study was to determine the bioequivalence of two azilsartan formulations after administration of single doses to healthy subjects under fasted and fed conditions.
These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sha Tin New Territories
-
Hong Kong, Sha Tin New Territories, Hong Kong, 000000
- Phase I Clinical Trial Centre, Chinese University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females between 18 and 40 (inclusive) years of age.
- Weight ≥ 50kg and the body mass index (BMI) within the range 19~24kg/m2 (inclusive);
- Negative urine hCG pregnancy test.
- Non-lactating women and willing to use appropriate contraceptive methods such as an intrauterine device (IUD), diaphragm with spermicides or abstinence or have a sterile sexual partner (e.g., vasectomy) during the whole study period. Men willing to use an appropriate method of contraception (such as condom with spermicide or use by partner of oral, implantable or injectable contraceptives, IUD, diaphragm, with spermicides) or abstinence or will have a sterile sexual partner during the whole study period;
- Subjects understand the nature, significance, possible benefits, inconveniences and potential risks before participating in this trial, understood the trial process, and are voluntary to sign the informed consent form and to participate in this trial.
Exclusion Criteria:
- Subjects who have abnormalities with clinical significance in physical examination, laboratory examinations, 12-lead ECGs, chest X-ray;
- Subjects with clinically significant history of orthostatic hypotension, chronic gastrointestinal disease (such as gastric ulcer, gastritis, etc.), renal disease (such as nephritis, pyelonephritis, etc.), or cardiovascular, respiratory, neurological, psychotic, haematological, endocrine or other disorders within the past 6 months before randomization or at the discretion of the investigators;
- Subjects with allergic history to Angiotensin Receptor Blockers or other anti-hypertensive drugs or anti-hypertensive biological agents;
- Sitting systolic blood pressure (SBP) <80mmHg or >140mmHg, and/or sitting diastolic blood pressure (DBP) <50mmHg or >90mmHg at screening;
- With the history of using any drug which will inhibit (chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid and sulphonamide) or induce liver metabolize drug (barbiturate, carbamazepine, aminoglutethimide, grifulvin, ethanol, ammonia methyl propyl, phenytoin, rifampin, glutethimide, dexamethasone, sulfinpyrazone) within 1 month before randomization;
- Vegetarian or abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits within the past 4 weeks prior to screening;
- History of alcohol abuse in the last 6 months prior to screening defined as an average weekly intake of greater than 14 unit (one unit is equivalent to 360ml of beer or 45ml of spirits with 40% alcohol content or 150 ml of wine); or subjects with positive alcohol breath test;
- History of smoking >5 cigarettes a day in the last 6 months prior to screening;
- History of drug abuse and taking drugs (such as marijuana, cocaine, opiates, benzodiazepines, amphetamines, barbiturates, tricyclic antidepressant) or subjects with positive urine drug abuse test results;
- Consumption of excessive amount of tea, coffee and/or caffeinated beverage (more than 8 cups/day, 200mL/cup) in the last 1 month prior to screening;
- Subjects who have participated in clinical trial (as subjects) in the last 3 months prior to screening;
- Blood donation of 250 ml or more in the 3 months prior to screening;
- Positive result of hepatitis B antigen, hepatitis C antibody, HIV antibody or syphilis antibody;
- Consumption of grapefruit juice, xanthine diet, chocolate, coffee or tea, carbonated beverages, or any other caffeinated beverages within 48 hours before randomization;
- Strenuous exercise within 48 hours before randomization;
- Administered any drugs (prescription medicine, over-the-counter drug, vitamins, supplements and Chinese herbal medicine) within 2 week before randomization; topical treatment is generally allowed or based on investigators' judgement.
- Subjects who, in the opinion of the investigators, should not participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azilsartan (Zhaoke) Under Fasting
Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
|
Azilsartan 20mg tablets from Zhaoke
Other Names:
|
Active Comparator: Azilsartan (Takeda) Under Fasting
Subjects will take a single Azilva 20mg Tablet under fasting condition
|
Azilva 20mg tablets from Takeda
Other Names:
|
Experimental: Azilsartan (Zhaoke) Under Fed
Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
|
Azilsartan 20mg tablets from Zhaoke
Other Names:
|
Active Comparator: Azilsartan (Takeda) Under Fed
Subjects will take a single Azilva 20mg Tablet under fed condition
|
Azilva 20mg tablets from Takeda
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence under Fasting Condition
Time Frame: 48 hours
|
48 hours
|
Bioequivalence under Fed Condition
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 22, 2018
Primary Completion (Actual)
June 25, 2018
Study Completion (Actual)
July 5, 2018
Study Registration Dates
First Submitted
August 28, 2018
First Submitted That Met QC Criteria
August 28, 2018
First Posted (Actual)
August 29, 2018
Study Record Updates
Last Update Posted (Actual)
August 29, 2018
Last Update Submitted That Met QC Criteria
August 28, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZK-HK-AZI-201705
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence of Two Azilsartan Formulations
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompletedPharmacokinetics of Novel Curcumin Formulations | Safety of Novel Curcumin FormulationsGermany
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompletedPharmacokinetics of New Curcumin Formulations | Safety of New Curcumin FormulationsGermany
-
Cyanotech CorporationUniversity of South FloridaCompleted
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
Repros Therapeutics Inc.CompletedComparison of 2 Different Formulations of 12 mg Proellex Vaginal CapsulesUnited States
-
Centre Hospitalier Régional d'OrléansCompletedComparison of Two Collimators During Bone ScintigraphyFrance
-
University of Campinas, BrazilStiefel, a GSK CompanyCompleted
-
Medical University of GrazRecruitingImmediate Implantation of Two-piece Zirconia Dental ImplantsAustria
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompletedEffect of Two Protocols of Ovarian Stimulation on Oocyte QualitySpain
-
Fundació Institut de Recerca de l'Hospital de la...CompletedTo Determine the Efficacy of Two Liquid Oxygen DeviceSpain
Clinical Trials on Azilsartan (Zhaoke)
-
Lee's Pharmaceutical LimitedCompleted
-
Hospital General de México Dr. Eduardo LiceagaUnknownHypertension | Obesity | Type 2 Diabetes MellitusMexico
-
TakedaCompleted
-
Arbor Pharmaceuticals, Inc.CompletedHypertensionUnited States, Brazil, Turkey, Poland, Mexico, Colombia, Italy, Argentina, Bulgaria, Hungary, South Africa, Ukraine
-
University of ChicagoTakedaCompleted
-
Nara Medical UniversityCompleted
-
Celltrion Pharm, Inc.CompletedEssential HypertensionKorea, Republic of
-
TakedaWithdrawnEssential Hypertension With Stable Angina and DyslipidemiaJapan
-
TakedaCompleted